UPDATED ON: Tuesday, June 19, 2012
From The Globe and Mail
GlaxoSmithKline Inc. (GSK) is pleased to announce the appointment of Paul Lirette as President with responsibility for all pharmaceutical operations in Canada.
“Paul brings over 20 years of global pharmaceutical experience having held international leadership roles with GSK in Canada, Europe and Australia. I am confident Paul will build on GSK’s strong foundation with his considerable commercial and management expertise across international markets,” said Deirdre Connelly, President, North America Pharmaceuticals.
A native of Montreal, Mr. Lirette first joined GSK in 1988. In 2001, he was appointed Vice-President of Sales & Marketing at GSK in Canada, where he led the company’s national sales operations and strategic marketing initiatives. Under his direction, Mr. Lirette demonstrated his commitment to putting patients first with the launch of PRIISME, a multidisciplinary primary care model empowering patients to manage their chronic disease.
During his tenure as Australasia Area Director and General Manager, which began in 2005, Mr. Lirette was nominated Managing Director of the Year for his work championing healthcare innovation.
Most recently, Mr. Lirette served as Senior Vice-President and Area Director for Central Europe where he oversaw pharmaceutical operations in 12 European countries, the Stiefel dermatology businesses in European markets, and led GSK’s operating model for immunology & hepatitis, supporting Europe, Emerging Markets & Asia Pacific/Japan. Mr. Lirette also served as Chair of the Central and Eastern European Task Force for the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Mr. Lirette holds an MBA from the Université de Sherbrooke and a Bachelor’s degree in Business Management from the Université du Québec à Montréal.
GSK is a leading research-based pharmaceutical company with a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better, and live longer.